Dr. Kenneth Walsh from the University of South Carolina, School of Medicine, and KD Pharma's CSO, Dr. Andrea Holmes, report on the pharmacology of a rare cannabinoid called delta 9-Tetrahydrocannabivarin (THCV). Delta 9-THCV is a non-psychotropic cannabinoid and does not cause a feeling of a "high" that delta 9-Tetrahydrocannabinol (THC) does. This psychotropic response of delta 9-THC is due to the strong binding to receptors in the brain called CB1 receptors that are in the endocannabinoid system. This research shows that Delta 9-THCV has the opposite effect on these CB1 receptors called antagonism and therefore provides pharmacokinetic evidence for its non-psychotropic response.
